Elevated levels of soluble urokinase receptor in serum from mycobacteria infected patients: Still looking for a marker of treatment efficacy

Scandinavian Journal of Infectious Diseases

Volumn 38, Issue 11-12, 2006, Pages 1028-1032

  Ostrowski, S R ^a   Ravn, P ^b   Hoyer Hansen, G ^c   Ullum, H ^a   Andersen, A B ^a  

^a University of Copenhagen   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c FINSEN LABORATORY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUMOR NECROSIS FACTOR RECEPTOR 2; UROKINASE RECEPTOR;

ADULT; ARTICLE; BACTERIUM CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LUNG TUBERCULOSIS; MALE; MICROSCOPY; MYCOBACTERIOSIS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM TUBERCULOSIS; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; TUBERCULOUS OSTEOMYELITIS; TUBERCULOUS SPONDYLITIS;

ADULT; ANTITUBERCULAR AGENTS; BIOLOGICAL MARKERS; COLONY COUNT, MICROBIAL; ENDPOINT DETERMINATION; FEMALE; HUMANS; INFLAMMATION; MALE; MYCOBACTERIUM TUBERCULOSIS; PROSPECTIVE STUDIES; RECEPTORS, CELL SURFACE; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 33845330610     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540600868305     Document Type: Article

References (20)

1. Ploug, M. (2003) Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor Current Pharmaceutical Design, 9, pp. 1499-528.
2. Nykjaer, A and Moller, B and Todd, RF and Christensen, T and Andreasen, PA and Gliemann, J and (1994) Urokinase receptor: An activation antigen in human T-lymphocytes Journal of Immunology, 152, pp. 505-16.
3. Plesner, T and Ralfkiaer, E and Wittrup, M and Johnsen, H and Pyke, C and Pedersen, TL and (1994) Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and haematopoietic tissue American Journal of Clinical Pathology, 102, pp. 835-41.
4. Coleman, JL and Gebbia, JA and Benach, JL. (2001) Borrelia burgdorferi and other bacterial products induce expression and release of the urokinase receptor (CD87) Journal of Immunology, 166, pp. 473-80.
5. Coleman, JL and Benach, JL. (2003) The urokinase receptor can be induced by Borrelia burgdorferi through receptors of the innate immune system Infection and Immunity, 71, pp. 5556-64.
6. Dekkers, PEP and ten Hove, T and Te Velde, AA and van Deventer, SJH and van der Poll, T. (2000) Up-regulation of monocyte urokinase plasminogen activator receptor during human endotoxaemia Infection and Immunity, 68, pp. 2156-60.
7. Juffermans, NP and Dekkers, REP and Verbon, A and Speelman, P and van Deventer, SJH and van der Poll, T. (2001) Concurrent up-regulation of urokinase plasminogen activator receptor and CD11b during tuberculosis and experimental endotoxaemia Infection and Immunity, 69, pp. 5182-5.
8. Kirchheimer, JC and Nong, YH and Remold, HG. (1988) Ifn-gamma, tumour necrosis factor-alpha, and urokinase regulate the expression of urokinase receptors on human monocytes Journal of Immunology, 141, pp. 4229-34.
9. Sitrin, RG and Todd, RF and Mizukami, IF and Gross, TJ and Shollenberger, SB and Gyetko, MR. (1994) Cytokine-specific regulation of urokinase receptor (Cd87) expression by U937 mononuclear phagocytes Blood, 84, pp. 1268-75.
10. Eugen-Olsen, J and Gustafson, P and Sidenius, N and Fischer, TK and Parner, J and Aaby, P and (2002) The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: A community study from Guinea-Bissau Int J Tuberc Lung Dis, 6, pp. 686-92.
11. Ostrowski, SR and Katzenstein, TL and Piironen, T and Gerstoft, J and Pedersen, BK and Ullum, H. (2004) Soluble urokinase receptor levels in plasma during 5 y of highly active antiretroviral therapy in HIV-1-infected patients J Acquir Immune Defic Syndr, 35, pp. 337-42.
12. Riisbro, R and Christensen, IJ and Piironen, T and Greenall, M and Larsen, B and Stephens, RW and (2002) Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumour tissue from patients with primary breast cancer Clinical Cancer Research, 8, pp. 1132-41.
13. Riisbro, R and Piironen, T and Brunner, N and Larsen, B and Nielsen, HJ and Stephens, RW and (2002) Measurement of soluble urokinase plasminogen activator receptor in serum Journal of Clinical Ligand Assay, 25, pp. 53-6.
14. Kjelsø C, Andersen P. Tuberkulose 2004. Epi-news, week 49.
15. Blasi, F and Carmeliet, P. (2002) uPAR: A versatile signalling orchestrator Nature Reviews Molecular Cell Biology, 3, pp. 932-43.
16. Almus-Jacobs, F and Varki, N and Sawdey, MS and Loskutoff, DJ. (1995) Endotoxin stimulates expression of the murine urokinase receptor gene in vivo Am J Pathol, 147, pp. 688-98.
17. Romer, J and Lund, LR and Eriksen, J and Pyke, C and Kristensen, P and Dano, K. (1994) The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelialization of mouse skin wounds J Invest Dermatol, 102, pp. 519-22.
18. Romer, J and Bugge, TH and Pyke, C and Lund, LR and Flick, MJ and Degen, JL and (1996) Impaired wound healing in mice with a disrupted plasminogen gene Nat Med, 2, pp. 287-92.
19. Solberg, H and Ploug, M and Hoyer-Hansen, G and Nielsen, BS and Lund, LR. (2001) The murine receptor for urokinase-type plasminogen activator is primarily expressed in tissues actively undergoing remodelling J Histochem Cytochem, 49, pp. 237-46.
20. de Bock, CE and Wang, Y. (2004) Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer Medicinal Research Reviews, 24, pp. 13-39.